Scinai CEO to Lead Israel Biopharma Manufacturing Roundtable at HealthIL 2026

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company with two complementary business units, has announced that its Chief Executive Officer Amir Reichman will co-lead a significant roundtable discussion during HealthIL Week 2026. The session, titled “Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale,” is organized by the Manufacturers Association of Israel and scheduled for January 19, 2026, at Expo Tel Aviv. This high-level forum will focus on Israel's biopharma development and manufacturing ecosystem, examining critical areas such as early-stage development, Chemistry, Manufacturing, and Controls (CMC) activities, and clinical manufacturing. The discussion will also assess the country's readiness for later-stage and commercial manufacturing, bringing together a diverse group of stakeholders including government agencies, biopharma manufacturers, Contract Development and Manufacturing Organizations (CDMOs), multinational pharmaceutical companies, biotech firms, and investors to explore current capabilities, identify structural gaps, and develop collaboration models that will shape the sector's future.

The company's involvement highlights its dual expertise through Scinai Bioservices, a boutique CDMO providing analytical method development, process development, and clinical cGMP manufacturing services for biotech clients worldwide, and Scinai R&D, which focuses on developing innovative Inflammation & Immunology (I&I) therapeutics based on NanoAbs (VHH antibody fragments). These unique antibody fragments possess distinctive physicochemical properties suitable for advanced mono- and multi-specific antibody formats, positioning Scinai at the forefront of therapeutic innovation. The roundtable represents a strategic opportunity for Scinai to contribute to industry dialogue and potentially influence policy and investment decisions within Israel's growing biopharma sector. For those interested in the full details, the complete press release is available through the InvestorBrandNetwork, which powers BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio that delivers comprehensive distribution and enhancement services for corporate news in the biotechnology and life sciences sectors.

This engagement comes at a pivotal time for Israel's biopharma industry, which has demonstrated remarkable innovation but faces challenges in scaling manufacturing capabilities to meet global demand. The roundtable's examination of collaboration models between various players—from early-stage biotechs to established multinationals—could yield insights that accelerate the translation of Israeli scientific discoveries into commercially viable therapies. As a company actively involved in both service provision and therapeutic development, Scinai's leadership in this discussion underscores its commitment to strengthening the entire biopharma value chain. The outcomes of this forum may influence investment flows, regulatory frameworks, and infrastructure development, ultimately affecting how quickly breakthrough treatments reach patients worldwide. For ongoing updates about Scinai Immunotherapeutics, investors can access the company's newsroom, which is part of the broader network that includes InvestorWire for efficient market communication and social media distribution to millions of followers.